Varvara Solodovnikova
A5001861047- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Infectious Diseases and Tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Diagnosis and treatment of tuberculosis
- Pneumonia and Respiratory Infections
- Pharmaceutical studies and practices
- COVID-19 Clinical Research Studies
- Mesenchymal stem cell research
- Long-Term Effects of COVID-19
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- Cardiac electrophysiology and arrhythmias
- Immunotherapy and Immune Responses
- Bone fractures and treatments
- Plant Pathogens and Fungal Diseases
- HIV/AIDS drug development and treatment
- Scientific and Engineering Research Topics
- Fungal Infections and Studies
- Computational Physics and Python Applications
- Bone and Joint Diseases
- Drug-Induced Hepatotoxicity and Protection
- AI in cancer detection
- Applied Advanced Technologies
- Cancer Immunotherapy and Biomarkers
Republican Scientific and Practical Centre of Pulmonology and Tuberculosis
2016-2025
BackgroundThe Xpert MTB/RIF assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance, but its sensitivity inadequate in patients with paucibacillary disease or HIV. Ultra (Xpert Ultra) was developed to overcome this limitation. We compared diagnostic performance for resistance.MethodsIn prospective, multicentre, accuracy study, we recruited adults pulmonary symptoms presenting at primary health-care centres hospitals eight countries...
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed evaluate the safety effectiveness of bedaquiline-containing regimens in a large, retrospective, observational conducted 25 centres 15 countries five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). admitted hospital for median (interquartile range (IQR)) 179 (92-280) days exposed 168...
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a acceptable side-effect profile than current needed.We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial to evaluate the efficacy safety of three 24-week, for tuberculosis. Patients in Belarus, South Africa, Uzbekistan who were 15 years age or older had pulmonary tuberculosis enrolled. stage 2 trial, 24-week regimen bedaquiline,...
Drug-resistant Mycobacterium tuberculosis is challenging elimination of (TB). We evaluated risk factors for TB and levels second-line drug resistance in M. patients Europe with multidrug-resistant (MDR) TB. A total 380 MDR 376 non-MDR were enrolled at 23 centers 16 countries during 2010-2011. 52.4% had never been treated TB, which suggests primary transmission tuberculosis. At initiation treatment 59.7% strains tested resistant to pyrazinamide, 51.1% ≥1 drug, 26.6% injectable drugs, 17.6%...
BackgroundAround 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety efficacy TB-PRACTECAL trial, evaluating oral regimens for tuberculosis.MethodsThis open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital community sites in Uzbekistan, Belarus, South Africa,...
Background Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes affected by TB COVID-19. Methods We collected from 174 centres in 31 countries on all COVID-19 between 1 March 2020 30 September 2022. Patients were followed-up until cure, death or end time. All had COVID-19; for analysis purposes, deaths attributed to TB, both. Survival was performed using Cox proportional...
Abstract Background Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)–based regimens have demonstrated higher rates success been recommended by the World Health Organization. Operational research is urgently required to evaluate these non-trial settings. Methods This was a prospective cohort study with microbiologically confirmed...
Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure even lower.To document the management outcome patients with MDR-TB Europe.We performed prospective cohort study, analyzing outcomes stratified by incidence of Treatment were compared World Health Organization alternative simplified definitions Tuberculosis Network European Trialsgroup (TBNET).A total 380 recruited followed up between 2010...
ABSTRACT Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on use QT-prolonging agents. Using data from randomized controlled trial, TB-PRACTECAL, we investigated differences in QTcF among participants three interventional arms: BPaL (bedaquiline, pretomanid, and linezolid), BPaLC (BPaL with clofazimine), BPaLM moxifloxacin). Additionally, assessed whether age, body mass index, country were causally associated prolongation. The trial included South Africa,...
We urgently need novel treatments for multidrug-resistant tuberculosis (MDR-TB). Autologous mesenchymal stromal cell (MSC) infusion is one such possibility due to its potential repair damaged lung tissue and boost immune responses. aimed assess the effectiveness of MSC improve outcomes among MDR-TB patients.We analyzed 108 Belarussian patients receiving chemotherapy. Thirty-six ("cases") also had MSCs extracted, cultured re-infused (average time from chemotherapy start was 49 days); another...
A significant drop in tuberculosis (TB) case-finding has been widely reported during the period of COVID-19 pandemic. To address a decrease TB notification, Belarus introduced laboratory testing patients with laboratory-confirmed coronavirus disease 2019 (COVID-19). We conducted secondary analysis health records among 844 diagnosis who were admitted to repurposed departments at hospitals and tested by Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) five regions between April October 2021....
Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety with bedaquiline longer than 190 days in individuals RR-TB under programmatic conditions. In prospective cohort study enrolling pulmonary patients, we initiated bedaquiline-based at tertiary hospital Belarus. defined standard use as <190 and prolonged ≥190 days. recorded adverse events (AEs) classified their seriousness relation to bedaquiline. Our primary...
There is limited evidence describing the safety and effectiveness of bedaquiline delamanid containing regimens in children adolescents with Multidrug-Resistant Tuberculosis (MDR-TB) Extensively Drug-Resistant (XDR-TB) globally. In this nationwide descriptive cohort study from Belarus, we examined adverse drug events, time to culture conversion, treatment outcomes including post-treatment recurrence among (<18 years age) treated and/or 2015 2019. Of 40 participants included (55% females;...
To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), National TB Programme in Belarus started using new drugs such as bedaquiline delamanid 2015-16. In this study, we assessed cardiovascular safety effectiveness (culture conversion, post-treatment recurrence) of delamanid-containing regimens adults (>18 years) MDR-TB or XDR-TB from June 2016 to February 2018. This was a nationwide cohort study...
We urgently need novel treatments for multidrug-resistant tuberculosis (MDR-TB). Autologous mesenchymal stromal cell (MSC) infusion is one such possibility due to its potential repair damaged lung tissue and boost immune responses. aimed assess the safety effectiveness of MSC improve treatment outcomes among MDR-TB patients. analyzed 108 Belarusian patients receiving chemotherapy. Thirty-six (cases) also had MSCs collected, extracted, cultured, reinfused (average time from chemotherapy start...
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) rifampicin (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise testing during MDR-TB treatment, despite being risk factor for drug-induced liver complications patients. This study investigates the co-treatment MDR/RR-TB HCV,...
This study evaluates the response of TB patients to treatment with autologous dendritic cell (DC) vaccine. There were 25 MDR⧹XDR pulmonary included in study. DCs obtained both from peripheral blood monocytes and bone marrow isolated stem cells using standard protocols. primed either M. tuberculosis lysates or CFP-10 peptides cultured maturation inducers. tested for immuno-phenotype, viability sterility injected into subcutaneously three times at 2- 3-week intervals. Clinical monitoring,...